Kaleido Biosciences, Inc. (KLDO): Price and Financial Metrics


Kaleido Biosciences, Inc. (KLDO): $0.05

-0.01 (-15.08%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KLDO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

KLDO POWR Grades


  • Stability is the dimension where KLDO ranks best; there it ranks ahead of 41.5% of US stocks.
  • The strongest trend for KLDO is in Momentum, which has been heading down over the past 146 days.
  • KLDO ranks lowest in Momentum; there it ranks in the 12th percentile.

KLDO Stock Summary

  • With a price/sales ratio of 86.68, Kaleido Biosciences Inc has a higher such ratio than 97.42% of stocks in our set.
  • The volatility of Kaleido Biosciences Inc's share price is greater than that of 96.67% US stocks with at least 200 days of trading history.
  • Kaleido Biosciences Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -99.9%, greater than the shareholder yield of only 3.85% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Kaleido Biosciences Inc are APTX, FGEN, XBIT, ORMP, and RAPT.
  • KLDO's SEC filings can be seen here. And to visit Kaleido Biosciences Inc's official web site, go to www.kaleido.com.

KLDO Valuation Summary

  • In comparison to the median Healthcare stock, KLDO's price/earnings ratio is 107.95% lower, now standing at -2.9.
  • KLDO's price/sales ratio has moved NA NA over the prior 30 months.
  • Over the past 30 months, KLDO's EV/EBIT ratio has gone up 3.4.

Below are key valuation metrics over time for KLDO.

Stock Date P/S P/B P/E EV/EBIT
KLDO 2021-08-31 212.0 5.2 -2.9 -2.4
KLDO 2021-08-30 206.8 5.1 -2.8 -2.3
KLDO 2021-08-27 214.4 5.3 -2.9 -2.4
KLDO 2021-08-26 205.4 5.0 -2.8 -2.3
KLDO 2021-08-25 207.5 5.1 -2.8 -2.3
KLDO 2021-08-24 208.6 5.1 -2.9 -2.3

KLDO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • KLDO has a Quality Grade of D, ranking ahead of 7.04% of graded US stocks.
  • KLDO's asset turnover comes in at 0.015 -- ranking 378th of 680 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows KLDO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.015 1 -4.553
2021-03-31 0.016 1 -4.096
2020-12-31 0.014 1 -3.775
2020-09-30 0.009 1 -3.624
2020-06-30 0.003 1 -4.107
2020-03-31 0.000 NA -5.249

KLDO Price Target

For more insight on analysts targets of KLDO, see our KLDO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $18.00 Average Broker Recommendation 1.75 (Moderate Buy)

KLDO Stock Price Chart Interactive Chart >

Price chart for KLDO

KLDO Price/Volume Stats

Current price $0.05 52-week high $0.13
Prev. close $0.06 52-week low $0.04
Day low $0.05 Volume 254,700
Day high $0.06 Avg. volume 950,478
50-day MA $0.00 Dividend yield N/A
200-day MA $0.00 Market Cap 2.28M

Kaleido Biosciences, Inc. (KLDO) Company Bio


Kaleido Biosciences, Inc. is a healthcare company, which focuses on leveraging the potential of the microbiome organ to treat disease and improve human health. The company was founded by Geoffrey von Maltzahn and Noubar B. Afeyan in 2015 and is headquartered in Lexington, MA.


KLDO Latest News Stream


Event/Time News Detail
Loading, please wait...

KLDO Latest Social Stream


Loading social stream, please wait...

View Full KLDO Social Stream

Latest KLDO News From Around the Web

Below are the latest news stories about Kaleido Biosciences Inc that investors may wish to consider to help them evaluate KLDO as an investment opportunity.

Global Blood's (GBT) Q4 Earnings Miss Mark, Revenues Rise Y/Y

Global Blood (GBT) reports wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly above estimates.

Yahoo | February 24, 2022

Kaleido Biosciences, Inc. (KLDO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Kaleido Biosciences, Inc. (KLDO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 23, 2022

Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?

On Novavax's (NVAX) fourth-quarter earnings call, investor focus is likely to be on the initial sales numbers of the company's COVID-19 vaccine.

Yahoo | February 23, 2022

Is a Beat Likely for Perrigo (PRGO) This Earnings Season?

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Yahoo | February 22, 2022

Blueprint Medicines (BPMC) Q4 Loss Widens, Revenues Top Mark

Blueprint Medicines (BPMC) misses on earnings while revenue beat estimates for the fourth quarter of 2021. Stock down.

Yahoo | February 17, 2022

Read More 'KLDO' Stories Here

KLDO Price Returns

1-mo -39.02%
3-mo -96.82%
6-mo -98.81%
1-year -99.29%
3-year -99.71%
5-year N/A
YTD -97.91%
2021 -73.74%
2020 81.27%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9208 seconds.